RxDoctor Payments Data

Hong Duong, MD

Internal Medicine · Westminster, CANPI 1275561417

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 49 payments — averaging $36.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$349
  • AbbVie$267
  • Cvrx, Inc.$203
  • Sunovion Pharmaceuticals Inc.$145
  • Novo Nordisk$134
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
  • plus $544 from 7 others

What the payments were for

  • Food & beverage$1,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$179,344
Medicare patients
160
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate21$15,077
EliquisApixaban41$14,572
EntrestoSacubitril/Valsartan13$8,605
JardianceEmpagliflozin15$7,751
Janumet XrSitagliptin Phos/Metformin Hcl11$6,079
Pantoprazole Sodium143$3,283
Betamethasone Dipropionate11$2,213
Dexlansoprazole DrDexlansoprazole11$1,996
Lidocaine11$1,765
Enoxaparin Sodium11$1,758
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$1,522
Atorvastatin Calcium191$1,162
Celecoxib25$870
Donepezil Hcl79$659
Carbidopa-LevodopaCarbidopa/Levodopa13$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$14,57241 claims
NovartisEntresto$105$8,60513 claims
Boehringer IngelheimJardiance$349$7,75115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →